Category «fda 2018»

Glycopyrrolate Tosylate

Glycopyrrolate Tosylate Molecular Formula: C26H35NO6S Molecular Weight: 489.627 g/mol (1,1-dimethylpyrrolidin-1-ium-3-yl) 2-cyclopentyl-2-hydroxy-2-phenylacetate;4-methylbenzenesulfonate CAS 873295-46-6 , C19 H28 N O3 . C7 H7 O3 S, Pyrrolidinium, 3-[(2-cyclopentyl-2-hydroxy-2-phenylacetyl)oxy]-1,1-dimethyl-, 4-methylbenzenesulfonate (1:1) Glycopyrronium tosylate monohydrate Molecular Formula, C19-H28-N-O3.C7-H8-O3-S.H2-O, Molecular Weight, 508.6522 https://chem.nlm.nih.gov/chemidplus/structure/1624259-25-1?maxscale=30&width=300&height=300 CAS 1624259-25-1, C19 H28 N O3 . C7 H7 O3 S . H2 O, Pyrrolidinium, 3-[(2-cyclopentyl-2-hydroxy-2-phenylacetyl)oxy]-1,1-dimethyl-, 4-methylbenzenesulfonate, hydrate (1:1:1) Dermira (Originator) DRM-04 DRM-04B DRM-04 tosylate monohydrate DRM04 DRM04 tosylate Glycopyrronium tosylate Glycopyrronium tosylate …

Lanadelumab, ラナデルマブ

(Heavy chain) EVQLLESGGG LVQPGGSLRL SCAASGFTFS HYIMMWVRQA PGKGLEWVSG IYSSGGITVY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAYRR IGVPRRDEFD IWGQGTMVTV SSASTKGPSV FPLAPSSKST SGGTAALGCL VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTVPSSSLGT QTYICNVNHK PSNTKVDKRV EPKSCDKTHT CPPCPAPELL GGPSVFLFPP KPKDTLMISR TPEVTCVVVD VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ YNSTYRVVSV LTVLHQDWLN GKEYKCKVSN KALPAPIEKT ISKAKGQPRE PQVYTLPPSR EEMTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP PVLDSDGSFF LYSKLTVDKS RWQQGNVFSC SVMHEALHNH YTQKSLSLSP G (Light chain) DIQMTQSPST LSASVGDRVT ITCRASQSIS SWLAWYQQKP …

Sodium zirconium cyclosilicate, ナトリウムジルコニウムシクロケイ酸塩

Sodium zirconium cyclosilicate ZS-9, ZS 9, UZSi-9 CAS 242800-27-7, H2 O3 Si . x H2 O . 2/3 Na . 1/3 Zr, Sodium zirconium cyclosilicate; Silicic acid (H2SiO3), Sodium zirconium(4+) salt (3:2:1), hydrate USAN CAS 17141-74-1, H6 O9 Si3 . 2 Na . Zr, Silicic acid (H2SiO3), sodium zirconium(4+) salt (3:2:1), hydrate, Sodium zirconium silicate (Na2ZrSi3O9) hydrate ナトリウムジルコニウムシクロケイ酸塩 ZrH4O6. 3H4SiO4. 2H2O. 2Na, 561.6068, AS IN kegg Molecular Formula, H6-O9-Si3.2Na.Z, Molecular Weight, 371.5004 …

Stiripentol, スチリペントール

Stiripentol スチリペントール STIRIPENTOL; Diacomit; 49763-96-4; BCX 2600; Estiripentol; Stiripentolum CAS: 137767-55-6 49763-96-4 (E)-1-(1,3-benzodioxol-5-yl)-4,4-dimethylpent-1-en-3-ol Molecular Formula: C14H18O3 Molecular Weight: 234.295 g/mol UNII R02XOT8V8I, Diacomit fda approval 2018/8/20 Stiripentol (marketed as Diacomit by Laboratoires Biocodex) is an anticonvulsant drug used in the treatment of epilepsy. It is approved for the treatment of Dravet syndrome, an epilepsy syndrome. It is unrelated to other anticonvulsants and belongs to the …

Plazomicin sulfate, プラゾマイシン硫酸塩 ,

Plazomicin Molecular FormulaC25H48N6O10 Average mass592.683 Da (2S)-4-Amino-N-[(1R,2S,3S,4R,5S)-5-amino-4-{[(2S,3R)-3-amino-6-{[(2-hydroxyéthyl)amino]méthyl}-3,4-dihydro-2H-pyran-2-yl]oxy}-2-{[3-désoxy-4-C-méthyl-3-(méthylamino)-β-L-arabinopyranosyl]oxy}-3-hyd roxycyclohexyl]-2-hydroxybutanamide [French][ACD/IUPAC Name] 1154757-24-0 [RN] 9522 ACHN-490 Plazomicin Sulfate Molecular Formula: C25H50N6O14S Molecular Weight: 690.763 g/mol Plazomicin Sulfate; UNII-A78L6MT746; Plazomicin Sulfate [USAN]; A78L6MT746; 1380078-95-4; Plazomicin sulfate (USAN), ACHN 490 sulfate 6′-(hydroxylethyl)-1-(haba)-sisomicin Plazomicin is a neoglycoside antibiotic with activity against a broad range of Gram-positive and Gram-negive pathogens. Plazomicin showed potent in …

BINIMETINIB, биниметиниб , بينيميتينيب , 美替尼 , ビニメチニブ

Binimetinib MEK-162 биниметиниб [Russian] [INN] بينيميتينيب [Arabic] [INN] 贝美替尼 [Chinese] [INN] ビニメチニブ 5-[(4-bromo-2-fluorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide 5-(4-Bromo-2-fluorophenylamino)-4-fluoro-1-methyl-1H-benzimidazole-6-carbohydroxamic acid 2-hydroxyethyl ester 6-(4-Bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide 606143-89-9 CAS C17H15BrF2N4O3, 441.227 UNII-181R97MR71 181R97MR71 1H-Benzimidazole-6-carboxamide, 5-[(4-bromo-2-fluorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl- STR……….http://www.who.int/medicines/publications/druginformation/innlists/PL109.pdf GET THE STRUCTURE tyrosine kinase inhibitor, antineoplastic Array BioPharma Inc;PHASE 3 Cancer, ovary (serous) Novartis PHASE 3 Melanoma CAS 606143-89-9 [RN] 9764 ARRY-162 ARRY-438162, NVP-MEK162 MEK-1 protein kinase inhibitor; MEK-2 protein kinase inhibitor Liver …

FDA approves first drug Oxervate (cenegermin) for neurotrophic keratitis, a rare eye disease

http://www.who.int/medicines/publications/druginformation/issues/77_INN_Recommended_List.pdf Active Substance General information The active substance in Oxervate, cenegermin, is a recombinant human Nerve Growth factor (rhNGF) produced in E. coli strain HMS174. The molecule is identical to human Nerve Growth factor (NGF), a naturally occurring human protein. In humans, NGF is naturally produced as pre-pro-peptide, secreted into the endoplasmic reticulum and cleaved …

Patisiran

Patisiran Sense strand: GUAACCAAGAGUAUUCCAUdTdT Anti-sense strand: AUGGAAUACUCUUGGUUACdTdT RNA, (A-U-G-G-A-A-Um-A-C-U-C-U-U-G-G-U-Um-A-C-dT-dT), complex with RNA (G-Um-A-A-Cm-Cm-A-A-G-A-G-Um-A-Um-Um-Cm-Cm-A-Um-dT-dT) (1:1), ALN-18328, 6024128 , ALN-TTR02 , GENZ-438027 , SAR-438037 , 50FKX8CB2Y (UNII code) for RNA, (A-U-G-G-A-A-Um-A-C-U-C-U-U-G-G-U-Um-A-C-dT-dT), complex with RNA(G-Um-A-A-Cm-Cm-A-A-G-A-G-Um-A-Um-Um-Cm-Cm-A-Um-dT-dT) (1:1) Nucleic Acid Sequence Sequence Length: 42, 21, 2112 a 7 c 7 g 4 t 12 umultistranded (2); modified CAS 1420706-45-1 Treatment of Amyloidosis, SEE…..https://endpts.com/gung-ho-alnylam-lands-historic-fda-ok-on-patisiran-revving-up-the-first-global-rollout-for-an-rnai-breakthrough/ Lipid-nanoparticle-encapsulated double-stranded siRNA targeting …

FDA approves lusutrombopag for thrombocytopenia in adults with chronic liver disease

FDA approves lusutrombopag for thrombocytopenia in adults with chronic liver disease https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm615348.htm synthesis………..https://newdrugapprovals.org/2015/08/20/lusutrombopag-oral-thrombopoietin-tpo-mimetic/ On July 31, 2018, the Food and Drug Administration approved lusutrombopag (Mulpleta, Shionogi Inc.) for thrombocytopenia in adults with chronic liver disease who are scheduled to undergo a medical or dental procedure. Approval was based on two randomized, double-blind, placebo-controlled trials (L-PLUS …

FDA approves first treatment Azedra (iobenguane I 131) for rare adrenal tumors

Iobenguane I 131 FDA approves first treatment for rare adrenal tumors The U.S. Food and Drug Administration today approved Azedra (iobenguane I 131) injection for intravenous use for the treatment of adults and adolescents age 12 and older with rare tumors of the adrenal gland (pheochromocytoma or paraganglioma) that cannot be surgically removed …